摘要
黑色素瘤是一种发生于黑色素细胞的恶性肿瘤,临床研究发现在晚期黑色素瘤患者中发生了BRAF(V600E)的突变。目前,临床上已批准的用于治疗BRAF突变黑色素瘤的靶向药物(如ipilimumab和vemurafenib)对黑色素瘤患者有很高的效率,与化疗相比能够明显延长无进展生存期和总生存期,但这些药物在体内所产生的效应是短暂的,大多数患者在不到1年内就会产生耐药。基于BRAF突变黑色素瘤耐药的现状,近几年对于其耐药机制的研究逐渐增多,该文对目前BRAF突变黑色素瘤耐药机制的研究进展及临床治疗策略进行综述,为临床的后续研究和治疗提供参考。
Melanoma is a malignant tumor originated from mela- nin ceils. Clinical researches indicate that BRAF （V600E） has been detected in about 50% of patients with advanced melano- ma. Currently, drugs （such as ipilimumab and vemurafenib ） that have been approved in clinical usage for treating BRAF-mu- tated melanoma show high responses and prolong the progress- free survival and overall survival significantly, as compared with chemotherapy. However, responses are often short-lived, andmost patients develop drug resistance within one year. Recently, an increasing number of studies on drug resistance have been conducted. This paper reviews the research progress of mecha- nisms for BRAF-mutated melanoma, it also includes discussion about the clinical therapy strategies, which may provide refer- ences for follow-up research and clinical treatment.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2013年第10期1349-1351,共3页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 81173174
81202655)
"十一五"科技支撑计划(No 2008BAI51B02)
教育部博士点基金资助项目(No 20113237110008)
关键词
黑色素瘤
BRAF突变
威罗菲尼
耐药
分子机制
治疗策略
melanoma
BRAF-mutated
vemurafenib
drug re- sistance
molecular mechanism
therapy strategy
